What autoimmune-related risks are highlighted for nivolumab in patients with pre-existing autoimmune disease?

For nivolumab (OPDIVO), observational studies suggest patients with pre-existing autoimmune disease may have a higher risk of immune-mediated adverse reactions following immune-checkpoint inhibitor therapy than patients without it, and underlying autoimmune disease flares were frequent but mostly mild and manageable.